Revolution Medicines, Inc. Warrant financials
$11.25+0.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $742.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $742.0K |
| Gross margin | — | — | — | — | — | — | — | — | — | — | 100.0% |
| Operating income | -$505.1M | -$445.2M | -$361.6M | -$315.3M | -$264.7M | -$240.8M | -$216.3M | -$175.7M | -$156.6M | -$140.9M | -$180.0M |
| Net income | -$644.4M | -$453.8M | -$364.9M | -$305.2M | -$247.8M | -$213.4M | -$194.6M | -$156.3M | -$133.2M | -$116.0M | -$161.5M |
| Net margin | — | — | — | — | — | — | — | — | — | — | −21770.5% |
| Diluted EPS | $-3.06 | $-2.29 | $-1.88 | $-1.61 | $-1.31 | $-1.13 | $-1.12 | $-0.94 | $-0.81 | $-0.70 | $-1.14 |
| EBITDA | -$502.7M | -$442.9M | -$359.3M | -$312.9M | -$262.7M | -$238.8M | -$214.3M | -$173.8M | -$154.7M | -$139.1M | -$180.0M |
| Operating cash flow | -$387.3M | -$354.2M | -$274.2M | -$207.3M | -$221.8M | -$194.4M | -$138.3M | -$130.4M | -$128.2M | -$160.6M | -$120.6M |
| Free cash flow | -$389.6M | -$355.7M | -$276.2M | -$210.7M | -$229.2M | -$197.7M | -$139.5M | -$133.9M | -$130.6M | -$163.7M | -$122.9M |
| Diluted shares | 210.9M | 198.1M | 194.6M | 189.2M | 188.6M | 188.1M | 174.2M | 166.8M | 165.1M | 164.7M | 141.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $815.4M | $440.9M | $383.7M | $217.4M | $402.4M | $333.6M |
| Short-term investments | $3.12B | $1.47B | $1.64B | $1.71B | $1.73B | $1.77B |
| Total debt | $487.4M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $4.32B | $2.25B | $2.35B | $2.25B | $2.43B | $2.37B |
| Total liabilities | $1.72B | $753.8M | $723.2M | $655.0M | $564.2M | $287.2M |
| Shareholders' equity | $2.61B | $1.50B | $1.63B | $1.60B | $1.87B | $2.08B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology